The Asian Pacific Association for the Study of the Liver [APASL]

Do join the ‘APCOLIS-II’ Study of APASL

CLD Attitudes and Practices during COVID-19 [CLAP-COVID] Study


Dear Colleague,
 
We want to thank you  for your continued support and active participation in APASL COVID-19 Liver Injury Spectrum Study (APCOLIS-I) study. The manuscript based on the initial 408 patients is under review.
 
The APASL Covid Task Force had made great efforts to prepare the Guidance for SARS-CoV-2 treatment in patients with liver disease. However, a lot of the recommendations were based on expert opinions. In order to further refine the Hepatology Parctices for future, the Task Force has decided to coduct another survey and get inputs from specialists across the world on management of  COVID-19 disease in patients with known or suspected liver disease. Your contribution and emnating information will be invaluable to formulate precise practice guidelines for our fraternity. The manuscript policy will be as per norms and subject to your contribution.
 
The APCOLIS-II survey is to be filled once and takes just about 10 minutes.
 

To join the ‘APCOLIS –II STUDY’,  ‘CLAP COVID’, please click 
https://www.surveymonkey.com/r/Apcolis-study

Dr Shiv Sarin, Dr. Tawesak Tanwandee, Dr. George Lau, Dr. Masao Omata
On behalf of APASL Covid Task Force